506.2K XNAS Volume
XNAS 08 Apr, 2025 5:30 PM (EDT)
IN8bio Inc Key Metrics
Default
All financials are in USD Million and price data in USD
VIEW MORE
Not Eligible
Expensive Valuation
Technically Bearish
Check Before You Buy
VIEW FULL CHECKLISTLow rank
5Positive14Negative
26.3% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
IN8bio Inc Stock Price Analysis
Week Price Range | 0.2 (LTP) 0.10.2 LowHigh |
Month Price Range | 0.2 (LTP) 0.10.3 LowHigh |
52 Week Price Range | 0.2 (LTP) 0.11.7 LowHigh |
IN8bio Inc Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get IN8bio Inc Stock Analysis
IN8bio Inc stock analysis with key metrics, changes, and trends.
| IN8bio Inc Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
|---|---|---|---|---|---|
| Annual Net Profit | $30.44 M | 1.43% | negative |
| |
| Price to Earning Ratio | -0.4 | - | negative |
| |
| Stock Price | $0.15 | -86.36% | negative |
| |
| Quarterly Net profit | $6.16 M | 18.93% | positive |
| |
| Debt to Equity Ratio | 0.35 | - | positive |
| |
| Return on Equity(ROE) | -154.44 % | -154.44% | negative |
| |
| Mutual Fund Holding | 11.54 % | -1.12% | negative |
| |
| Institutional Holding | 36.73 % | 0% | neutral |
| |
Loading data..
IN8bio Inc - Company Profile
What does IN8bio Inc do?
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
IN8bio Inc Management structure
All Gross Remunerations are in USD